Skip to main content

Research Repository

Advanced Search

Budesonide treatment for microscopic colitis: systematic review and meta-analysis

Sebastian, Shaji; Wilhelm, Annika; Lisle, Jessica; Myers, Sally; Veysey, Martin

Authors

Shaji Sebastian

Annika Wilhelm

Jessica Lisle

Sally Myers

Martin Veysey



Abstract

Microscopic colitis (MC), encompassing lymphocytic and collagenous colitis, is a common cause for chronic nonbloody diarrhoea, which impacts significantly on the quality of life for patients. Despite increasing awareness of the condition and its treatment, there is considerable variation in therapeutic approaches. To conduct a systematic review and meta-analysis on the efficacy and safety of budesonide in the treatment of MC. We searched Medline, Embase and Central databases using predefined search methodology for randomised trials using budesonide in the treatment of MC. We extracted data, on the efficacy and safety of budesonide, from studies identified that met the feasibility for analysis criteria. These data were pooled with a fixed effects model. Nine studies met the inclusion criteria for analysis. The pooled odds ratios (ORs) for a response to budesonide therapy at induction and maintenance were 7.34 [95% confidence interval (CI): 4.08–13.19] and 8.35 (95% CI: 4.14–16.85) respectively. Histological response rates were superior in budesonide-treated patients compared to placebo following induction (OR: 11.52; 95% CI: 5.67–23.40) and maintenance treatment (OR: 5.88; 95% CI: 1.90–18.17). There was no difference in adverse events. Significant relapse rates (>50%) were observed following treatment cessation with no difference noted between the budesonide or the placebo-treated patients. Budesonide is an effective treatment option for MC for achieving induction and maintenance of both clinical and histological response. High relapse rates on treatment cessation were observed.

Citation

Sebastian, S., Wilhelm, A., Lisle, J., Myers, S., & Veysey, M. (2019). Budesonide treatment for microscopic colitis: systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 31(8), 919–927. https://doi.org/10.1097/MEG.0000000000001456

Journal Article Type Article
Acceptance Date Mar 29, 2019
Online Publication Date Jun 17, 2019
Publication Date 2019-08
Deposit Date Jun 18, 2019
Publicly Available Date Jun 19, 2019
Journal European Journal of Gastroenterology and Hepatology
Print ISSN 0954-691X
Publisher Lippincott, Williams & Wilkins
Peer Reviewed Peer Reviewed
Volume 31
Issue 8
Pages 919–927
DOI https://doi.org/10.1097/MEG.0000000000001456
Keywords Budesonide; Collagenous colitis; Lymphocytic colitis; Meta-analysis; Microscopic colitis; Therapies
Public URL https://hull-repository.worktribe.com/output/2003314
Publisher URL https://journals.lww.com/eurojgh/Abstract/publishahead/Budesonide_treatment_for_microscopic_colitis_.97792.aspx
Additional Information This is a non-final version of an article published in final form in : Sebastian, S., Wilhelm, A., Lisle, J., Myers, S., & Veysey, M. (in press). Budesonide treatment for microscopic colitis: systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, https://doi.org/10.1097/MEG.0000000000001456
Contract Date Jun 19, 2019

Files






You might also like



Downloadable Citations